Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease – A meta-analysis

Peripheral artery disease (PAD) is associated with increased risk of cardiovascular events. The benefits of dual antiplatelet therapy (DAPT) vs single antiplatelet therapy (SAPT) with aspirin in patients with PAD remain subject of ongoing debate. We performed a meta-analysis of studies comparing DAP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2018-10, Vol.269, p.292-297
Hauptverfasser: Navarese, Eliano P., Wernly, Bernhard, Lichtenauer, Michael, Petrescu, Aniela M., Kołodziejczak, Michalina, Lauten, Alexander, Frediani, Lara, Veulemanns, Verena, Wanha, Wojciech, Wojakowski, Wojciech, Lesiak, Maciej, Ferrante, Giuseppe, Zeus, Tobias, Tantry, Udaya, Bliden, Kevin, Buffon, Antonino, Contegiacomo, Gaetano, Jung, Christian, Kubica, Jacek, Pestrichella, Vincenzo, Gurbel, Paul A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Peripheral artery disease (PAD) is associated with increased risk of cardiovascular events. The benefits of dual antiplatelet therapy (DAPT) vs single antiplatelet therapy (SAPT) with aspirin in patients with PAD remain subject of ongoing debate. We performed a meta-analysis of studies comparing DAPT vs aspirin monotherapy in PAD. Incidence rate ratios (RR) and respective 95% confidence intervals (CI) were used as summary statistics. The primary outcome was mortality. Secondary endpoints were ischemic and bleeding outcomes. Ten studies including 65,675 patients have been included. Compared to SAPT, DAPT was associated with a significant reduction in mortality: RR, 0.89; 95% CI, 0.86–0.92; P 
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2018.07.009